Related Experiment Video
Updated: Mar 15, 2026
12:48
Blood Collection from the American Horseshoe Crab, Limulus Polyphemus
Published on: October 13, 2008
30.9K
To neither bleed nor clot: That is the question
Rhian E Davies1, Ian C Gilchrist2
1Division of Cardiology, Penn State University, College of Medicine, Heart and Vascular Institute, MS Hershey Medical Center, Hershey, Pennsylvania.
Summary
Patients with atrial fibrillation (AF) undergoing stenting with thin-strut cobalt-chrome stents may have outcomes similar to those without AF. Careful management is crucial to balance bleeding and thrombotic risks associated with antithrombotic therapies.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Research
Background:
- Patients with atrial fibrillation (AF) undergoing coronary stenting present unique management challenges.
- Triple antithrombotic therapy increases bleeding risk, while withholding anticoagulation or truncating antiplatelet therapy raises thrombotic risk.
Discussion:
- Optimal antithrombotic strategies for AF patients receiving thin-strut cobalt-chrome stents remain unclear.
- Current management relies heavily on expert consensus due to limited clinical studies.
- Expanding use of guideline-based oral anticoagulation for AF increases the number of such patients in cardiac catheterization labs.
Key Insights:
- Thin-strut cobalt-chrome stents may offer comparable outcomes for AF patients versus non-AF patients.
- Balancing antithrombotic therapy is critical to mitigate both bleeding and thrombotic complications.
- Evidence-based guidelines for managing AF patients undergoing stenting are needed.
Outlook:
- Further research is essential to establish definitive antithrombotic protocols.
- Clinical trials are needed to guide management decisions for this growing patient population.
- Personalized antithrombotic strategies may improve outcomes for AF patients with coronary stents.
Related Concept Videos
01:24Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:05Introduction to Hemostasis
15.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
14.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:22Formation of the Platelet Plug
10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K